Purpose: To identify variations in renal function and histology between Caucasian Americans (CA) and African Americans (AA) undergoing robotic nephron-sparing surgery (NSS).

Methods: A retrospective chart review was performed on patients who underwent NSS. Multivariate analysis identified factors affecting postoperative estimated glomerular filtration rate (eGFR). Histology was re-reviewed by pathology to confirm papillary type.

Results: A total of 331 patients underwent NSS: CA (n = 212), AA (n = 105), Hispanic (n = 10), and other (n = 4). AA average age (60.1 years) was lower than CA (62.3 years) (P < .001), with a higher proportion of AA women (46%) than CA (37%) (P = .021). AA had a higher incidence of diabetes (58.2%) and hypertension (93.9%). Preoperative average eGFR was similar: 70.35 mL/min for AA versus 69.06 mL/min for CA. Average postoperative eGFR was 50.59 mL/min for AA and 57.85 mL/min for CA. Postoperative creatinine increased more in AA (0.44 mg/dL) versus CA (0.33 mg/dL) (P < .001) even when stratified by pathological stage. Clear cell renal cell carcinoma (RCC) was the most common histology with AA (45%) and CA (60%). A greater than 2-fold higher incidence of papillary RCC was observed in AA (31%) versus CA (13%). AA exhibited a greater proportion of high-grade or type 2 papillary RCC (40% and 30%) versus CA (25% and 13%).

Conclusions: AA patients were treated at a younger age, with a larger proportion of women. Postoperatively, AA experienced a greater increase in serum creatinine. Final histology demonstrated greater papillary RCC incidence in AA and increased likelihood for type 2 papillary RCC, a more aggressive histology.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2016.07.013DOI Listing

Publication Analysis

Top Keywords

papillary rcc
16
robotic nephron-sparing
8
nephron-sparing surgery
8
patients underwent
8
underwent nss
8
p < 001
8
proportion women
8
higher incidence
8
type papillary
8
histology
6

Similar Publications

renal transplant carcinoma, especially in the context of bilateral renal carcinoma, is rare and often presents as small, low-grade papillary renal cell carcinoma (RCC). There is currently no consensus or effective treatment for advanced metastatic RCC after kidney transplantation. A 40-year-old man developed renal transplant carcinoma with venous thrombus and lung metastases 13 years after transplantation.

View Article and Find Full Text PDF

Tubulocystic renal cell carcinoma (TC-RCC) is uncommon and is defined by exclusive tubulocystic growth. Its clinicopathology is still evolving. Twenty-eight cases of so-defined TC-RCC were studied for clinicopathology as well as, in some cases, immunohistochemistry.

View Article and Find Full Text PDF

Objective: Clinical trials have demonstrated the efficacy and safety of avelumab + axitinib in patients with advanced clear cell renal cell carcinoma (ccRCC). However, information is limited regarding the activity of avelumab + axitinib in patients with non-clear cell RCC (nccRCC). In Japan, post-marketing surveillance (PMS) of patients with RCC receiving avelumab + axitinib treatment in general clinical practice was undertaken.

View Article and Find Full Text PDF

Non-clear cell renal cell carcinoma narrative review: where we are in 2024.

Transl Cancer Res

November 2024

Division of Hematology and Oncology, Department of Internal Medicine, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA.

Article Synopsis
  • Advances in understanding non-clear cell renal cell carcinoma (RCC) have improved due to better molecular and genetic testing, helping to identify specific subtypes and personalize treatment.
  • Representation in clinical trials for rare non-papillary RCC variants is limited, making evidence-based management difficult.
  • The shift toward molecular diagnostics is enhancing our knowledge of RCC behaviors and responses to treatments, although most evidence comes from smaller clinical studies rather than extensive trials.
View Article and Find Full Text PDF

Background: N-acetyltransferase 10 () is a lysine acetyltransferase known for catalyzing the N4-acetylcytidine (ac4C) modifications on RNAs. Recent studies have associated with the pathogenesis of various cancers. However, its specific function and prognostic significance in papillary renal cell carcinoma (pRCC) remain poorly understood.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!